Item 8.01. Other Events
On November 15, 2021, Humacyte, Inc. (the "Company") issued a press release
announcing data from a Phase 2 clinical trial of patients receiving the human
acellular vessel (HAV) produced using the Company's cutting-edge, large-scale
manufacturingsystems, known as "LUNA200," for vascular access in hemodialysis. A
copy of this press release is filed as Exhibit 99.1 to this Current Report on
Form 8-K and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
Exhibit
Number Description
99.1 Press release, dated November 15, 2021.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
1
© Edgar Online, source Glimpses